Study details								
First author surname year	r of publicat	ion:						
Country:								
Study design:								
Study setting (e.g., outbrea	ık investigati	on, commu	nity-based - s	pecify):				
Number of centres:								
Total length of follow up (if applicable	e):						
Funding (government/priva	ate/manufact	urer/other -	specify):					
Aim of the study								
Subgroup of interest (i.e.,	children, re	cently arri	ved people, ii	nmunocompromise	ed people)			
Participants								
Recruitment dates:								
Total N of recruited paties	nts:							
Inclusion criteria:								
Exclusion criteria:								
Total N of excluded patien	ıts:							
Total N of patients tested	with both IC	GRA and T	TST:					
Total N of patients with v	alid results t	for both IC	GRA and TST	':				
Methods of active TB diag	gnosis (if ap	plicable):						
Outcomes (study-based) li	ist:							
Characteristics of particip	oants (total s	study samp	ole)					
Mean (range or SD) age (ye	ears):							
Women (n [%]):								
Race/ethnicity (n [%]):								
Geographic origin (n[%]):								
BCG vaccination (n [%]):	BCG vaccination (n [%]):							
	History of anti-TB treatment (n [%]):							
	Total incidence of active TB (n [%]):							
Chest radiography (yes/no)								
Clinical examination (yes/n	o):							
Morbidity (n [%]):								
	Co-morbidity (n [%]):							
Type of during-study treatn								
Number of patients tested								
	Total N	Total N	Total N	Total N	Total N			
	(tested)	(test+)	(test-)	(indeterminate)	(test results			
TGD 1 (CC)					available)			
IGRA (specify):								
TST:								
Test 3 (specify)								
Total N of patients with valid results for both IGRA and TST:								
Levels/groups of exposure to TB in increasing order (if applicable):								
Definition of exposure group								
Non-exposed								
Exposed 1 (specify):								
Exposed 2 (specify):								
Exposed 3 (specify):								
Exposed 4 (specify):								

Name of first reviewer: Name of second reviewer:

Tests										
		for 1	Assay us thodology, test measu manufact	timing rement,			er informa	ormation		
IGRA										
TST										
Association between			s and incid	lence of a	ctive TB (if appli	cable	,			
	IGR						TST			
	Incid			Total			ncidenc		Total	
		ive [ГВ				active [ГВ		
	Yes		No			Y	Zes	No		
IGRA +					TST +					
IGRA -					TST -					
indeterminate					indeterminate	;				
Total					Total					
			Test per	formance	parameters					
	IGR	A					TST			
Sensitivity =					Sensitivity =					
Specificity =					Specificity =					
PPV =					PPV =					
NPV =					NPV =					
Cumulative Incidence	e _{IGRA+} =	=			Cumulative In	ciden	ce _{TST+}	=		
Cumulative Incidence	e _{IGRA-} =				Cumulative In	Cumulative Incidence _{TST} =				
Cumulative Incidence	e Ratio I	GRA	=		Cumulative In	Cumulative Incidence Ratio _{TST} =				
Incidence density rate					Incidence den	Incidence density rate _{TST+} =				
Incidence density rate _{IGRA} .=				Incidence den	Incidence density rate TST- =					
Incidence density rate ratio $_{IGRA} =$ Incidence density rate ratio $_{TST} =$										
·				etween tes	sts (IGRA vs. TS					
Ratio of cumulative is	ncidenc	e rat	ios =		,					
Ratio of incidence de										
Other reported measu	ıre =									
*		wee	n test resu	lts and lev	vels of TB exposu	ıre (if	f applic	able)		
	IGRA				1		TST	//		
	Exp				Exposui	xposure level Total				
			Low/No	-				Low/No		
IGRA +					TST +		,			
IGRA -					TST -					
indeterminate					indeterminate					
Total					Total					
			Test per	formance	parameters					
	IGRA	<u> </u>				r	TST			
Sensitivity =					Sensitivity =					
Specificity =			Specificity =							
PPV =			PPV =							
			NPV =							
DOR (for T ⁺ calculated) =				DOR (for T ⁺ calculated) =						
OR (crude; for T ⁺ reported) =			OR (crude; for T reported) =							
OR (regression-based; reported) =			OR (regression-based; reported) =							
List of covariates:			List of covariates:							
Other reported measure =				Other reported measure =						
Comparison between tests (IGRA vs. TST)										
Ratio of DORs (for T					(20221 151 15	-,				
101 1	carcur	area	,							

Ratio of OR (crude; for T ⁺ 1	eported) =	=					
Ratio of ORs (regression-based; reported) =							
Other reported measure =							
Between-test agreement, concordance, and discordance (if applicable)							
This table may be stratified by TST cut-off value, BCG vaccination status, and/or condition							
Total sample							
		TST +	TST -	Total			
IGRA +							
IGRA -							
indeterminate							
Total							
Description							
Sample definition (e.g., tota	ıl, if strati	fied by BCG or c	ondition – specify):				
TST + threshold:							
Parameters							
Kappa =							
% concordance =							
% discordance =							
Stratification (specify gro	up 1)						
		TST +	TST -	Total			
IGRA +							
IGRA -							
indeterminate							
Total							
Description							
Sample definition (e.g., tota	ıl, if strati	fied by BCG or c	ondition – specify):				
TST + threshold:							
Parameters							
Kappa =							
% concordance =							
% discordance =							
Stratification (specify gro	up 2)						
		TST +	TST -	Total			
IGRA +							
IGRA -							
indeterminate							
Total							
Description							
Sample definition (e.g., tota	ıl, if strati	fied by BCG or c	ondition – specify):				
TST + threshold:							
Parameters							
Kappa =							
% concordance =							
% discordance =							
Other outcomes							
Test and cut-off (if application)	able)	Adverse events	n/N (%)	Health related			
		(specify)		quality of life			
				mean score			
				(SD) (specify)			
IGRA:							
TST:							
Test 3 (specify):							
Conclusions							

Authors:		
Reviewers:		

Abbreviations: DOR = diagnostic odds ratio; 95% CI = 95 percent confidence intervals; TB = tuberculosis; BCG = Bacillus Calmette—Guérin; PPV = positive predictive value; NPV = negative predictive value; FPR = false positive rate; FNR = false negative rate; SD = standard deviation